Paroxetine and bupropion have no in vitro effects on lynphocyte proliferation and viability Paroxetina e bupropiona não apresentam efeito na viabilidade nem na proliferação de linf... by Ramiro Ronchetti, Mariana Dal Pizzol, Rodrigo Pestana Lopes, Rachel Rubin da Silva, Gabriel José Chittó Gauer, Moisés Evandro Bauer

“…These results indicate a more favorable effect of such psychopharmacological drugs when compared to reported immunological effects associated with tryciclic antidepressants.…”
Get full text

Does prescribing long acting antipsychotic injection increase mortality or morbidity in patients who continue to use illicit drugs? by N. Sud

“…Results A review of psychopharmacological properties of first and second generation LAI (Taylor 2009) noted that use is complicated by adverse effects and confusion over dose response relationships. …”
Get full text

Case report: Psychosis with catatonia in an adult man: a presentation of neurosarcoidosis by Griet Van Hoye, Barbara Willekens, Barbara Willekens, Barbara Willekens, Stephanie Vanden Bossche, Stephanie Vanden Bossche, Manuel Morrens, Manuel Morrens, Filip Van Den Eede, Filip Van Den Eede

Get full text

Access to a psychiatric emergency setting during the COVID-19 pandemic: focus on youth populations by F. Masini, G. Caramanico, G. Menculini, G. Latini, F. De Giorgi, K. Amantini, P. Moretti, A. Tortorella

“…Substance-related disorders were significantly reduced (8.0% vs 15.8%, p=0.016) after the COVID-19 outbreak. About psychopharmacological treatment, there was an increase in people who had received treatment in the past but were no longer on treatment (52.3% vs 30.8%, p<0.001). …”
Get full text

Lurasidone augmentation to clozapine in treatment resistant schizophrenia: A pilot study by V. Arienti, S. C. Civardi, F. Besana, F. Mazzoni, G. Carnevale Miacca, N. Brondino, P. Politi, M. Olivola

“…Methods We conducted an observational study in a sample of 20 patients diagnosed with treatment resistant schizophrenia, based on DSM-5 diagnostic criteria and psychopharmacologic history. Treatment choices were taken independently by clinicians in charge of each patient. 10 subjects underwent Lurasidone augmentation of Clozapine, whereas the remaining 10 subjects were treated as usual with Clozapine and another atypical antipsychotic. …”
Get full text

ANXIETY-DEPRESSIVE DISORDER IN A PATIENT WITH GRAVES’ DISEASE AND PSYCHOSOCIAL PROBLEMS by M. Betriu, C. Becerra, S. Garcia, A. Vidal, E. Castan

“…Later, with the adequate intake of the psychopharmacological treatment, aims a complete resolution of symptoms. …”
Get full text

Akathisia after chronic usage of synthetic cathinones: A case study by Niels Albert, Niels Albert, Kirsten Catthoor, Kirsten Catthoor, Manuel Morrens, Manuel Morrens

Get full text

Laughing gas-induced psychotic disorder : Case report from Morocco. by B. Zineb, T. Aicha, K. Imane, S. Maria, E. O. Fatima

“… Introduction In the current psychopharmacological panorama, the variety of substances capable of inducing an acute psychotic episode and which have entered the habits of drug addicts has rapidly increased. …”
Get full text

Anxiety and Obesity in Children: Anti-oxidative Medications and Hyperbaric Oxigenation Therapy by D. Labunskiy, G. Kukina, M. Kolmykova, S. Kiryukhina

“…Conclusions The use of antioxidant therapy in combination with psychopharmacological drugs has long been a well-established method of treatment for a variety of psychopathological conditions. …”
Get full text

Psychosocial versus pharmacological treatments for deliberate self harm. by Hawton, K, Townsend, E, Arensman, E, Gunnell, D, Hazell, P, House, A, van Heeringen, K

“…SELECTION CRITERIA: All RCTs of psychosocial and/or psychopharmacological treatment versus standard or less intensive types of aftercare for patients who shortly before entering a study engaged in any type of deliberately initiated self-poisoning or self-injury, both of which are generally subsumed under the term deliberate self-harm. …”

ON THE DIFFICULTIES IN THE DIFFERENTIAL DIAGNOSIS BETWEEN PRIMARY DEPERSONALIZATION-DEREALIZATION DISORDER AND SCHIZOTYPAL DISORDER by Anastasia Yu. Bykova, Roman A. Bekker, Yuriy V. Bykov

“…In the field of psychiatry, making the correct diagnosis is also of great practical importance for choosing the correct strategy and tactics of treatment, both psychopharmacological and psychotherapeutic. Our data also convincingly indicate that, unfortunately, in Russia and post-Soviet countries, overdiagnosis of STE is extremely common in cases where the patient actually has primary DPD, or depersonalization-derealization syndrome (DP/DR syndrome) within the clinical picture of some other mental disorder (usually from an anxiety disorders spectrum or from affective disorders spectrum), as well as a misunderstanding of what the DP/DR syndrome is, what are the typical symptoms and phenomenology of it, together with underestimation of its importance in the overall clinical picture of any given mental disease, underestimation of the importance of specific measures to eliminate the DP/DR syndrome in a given patient, and insufficient ability of specialists to diagnose and treat this devastating syndrome. …”
Get full text

“Keeping an eye on amylase”. Side effects of antidepressants by T. Jiménez Aparicio, G. Medina Ojeda, A. Rodríguez Campos, L. Rodríguez Andrés, C. Vallecillo Adame, C. De Andrés Lobo, M. Queipo de Llano de la Viuda, G. Guerra Valera, A. A. Gonzaga Ramírez, M. J. Mateos Sexmero, M. Fernández Lozano, B. Rodríguez Rodríguez, N. Navarro Barriga, M. P. Pando Fernández, P. Martínez Gimeno, M. Calvo Valcárcel, M. A. Andreo Vidal

“…During this admission, psychopharmacological treatment was started for the first time, on that occasion with a selective serotonin reuptake inhibitor (SSRI), treatment of first choice (3). …”
Get full text

“The cat and the calcium”. A case of delirium secondary to hypercalcaemia. by T. Jiménez Aparicio, C. Vallecillo Adame, C. de Andrés Lobo, G. Medina Ojeda, M. Queipo de Llano de la Viuda, A. A. Gonzaga Ramírez, G. Guerra Valera, M. Fernández Lozano, M. J. Mateos Sexmero, B. Rodríguez Rodríguez, N. Navarro Barriga, M. A. Andreo Vidal, M. Calvo Valcárcel, P. Martínez Gimeno, M. P. Pando Fernández, I. D. L. M. Santos Carrasco, J. I. Gonçalves Cerejeira

“…Delirium has a prevalence between 1 and 2% in the general population (2). Psychopharmacological treatment is used symptomatically, with antipsychotics (3). …”
Get full text

The impact of lifestyle on adherence to treatment in a sample of patients with Major Depression by D. Conti, N. Girone, S. Vanzetto, M. Cocchi, F. Achilli, S. Leo, M. Bosi, B. Benatti, B. Dell’Osso

“…Moreover, adherence to psychopharmacological treatment was assessed using the Clinician Rating Scale (CRS; Kemp et al, 1996; 1998). …”
Get full text

EFFECTS OF SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS, BIOLOGICAL AGENTS, AND PSYCHOPHARMACOTHERAPY ON THE MENTAL DISORDERS IN PATIENTS WITH RHEUMATOID ARTHRITIS by A. A. Abramkin, T. A. Lisitsyna, D. Yu. Veltishchev, O. F. Seravina, O. B. Kovalevskaya, E. L. Nasonov

“…Mental disorders (MDs) of the anxiety-depressive spectrum (ADS) and cognitive impairment (CI) are characteristic of the majority of patients with rheumatoid arthritis (RA); however, the effects of disease-modifying antirheumatic drugs (DMARDs), biological agents (BAs), and their combinations with psychopharmacological drugs (PPDs) on these abnormalities have been insufficiently studied. …”
Get full text